Management of Renal Parenchymal Disease

Initial Diagnostic Assessment and Risk Stratification

The American Heart Association recommends identifying the underlying cause of renal parenchymal disease through clinical history, physical examination, and targeted testing, including obtaining renal ultrasound to diagnose polycystic kidney disease 4
The European Society of Cardiology suggests checking for unprovoked hypokalemia, hypercalcemia, or elevated creatinine with abnormal urinalysis to confirm renal parenchymal disease 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends targeting systolic BP <120 mmHg using standardized office measurement in most adult patients with renal parenchymal disease, and for children, targeting 24-hour mean arterial pressure ≤50th percentile for age, sex, and height by ambulatory monitoring 1
The American College of Cardiology suggests that ACE inhibitors or ARBs are mandatory first-line agents when proteinuria is present, and should be started at low doses and titrated every 5-7 days to maximally tolerated or allowed daily dose 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends using loop diuretics as the primary treatment for fluid overload in renal parenchymal disease, and diuretics are preferred agents along with dietary sodium restriction (<2.3 g/day or <90 mmol/day) 1
The European Renal Association suggests monitoring closely for hyponatremia, hypokalemia, GFR reduction, and volume depletion when using diuretics 1

The American Diabetes Association recommends initiating SGLT2 inhibitors when proteinuria exceeds 300 mg/g or diabetes is present, as they reduce cardiovascular death or heart failure hospitalization by 31% and composite renal outcomes by 30% 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests that SGLT2 inhibitors can be started with eGFR as low as 20 mL/min/1.73 m², and provide benefits independent of glucose-lowering effects 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends up-titrating ACE inhibitor or ARB to maximally tolerated dose as first-line therapy to reduce proteinuria, and advises sodium restriction to enhance antiproteinuric effect of RAS inhibitors by 30-50% 1
The American College of Cardiology suggests that the goal is to reduce proteinuria to <1 g/day when initial levels are ≥300 mg/g, and to treat metabolic acidosis if serum bicarbonate is <22 mmol/l 1

The American College of Cardiology recommends initiating statin therapy immediately regardless of LDL-C level in patients with diabetes and renal parenchymal disease, with a target LDL-C <70 mg/dL in very high-risk patients with diabetes and proteinuria 3
The European Atherosclerosis Society suggests considering statin/ezetimibe combination for non-dialysis-dependent CKD, and monitoring lipids 4-12 weeks after initiation, then annually if at goal 6

The American Diabetes Association recommends optimizing glycemic control to HbA1c <7% in diabetic patients with renal parenchymal disease, and considering GLP-1 receptor agonists for cardiovascular risk reduction if cardiovascular disease is predominant 3
The European Association for the Study of Diabetes suggests that tight glycemic control independently reduces microvascular complications and cardiovascular events, and that metformin is contraindicated when eGFR <30 mL/min/1.73 m² 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends implementing comprehensive dietary and lifestyle changes, including restricting dietary sodium to <2.0 g/day, adopting healthy and diverse diets, and maintaining protein intake of 0.8 g/kg body weight/day in adults with CKD G3-G5 1
The American Heart Association suggests achieving weight normalization if BMI >25 kg/m², stopping smoking immediately, and recommending at least 150 minutes per week of moderate-intensity aerobic plus resistance activity 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends serial monitoring of serum creatinine, electrolytes, and body weight every 5-7 days during acute titration phase, and checking renal function and potassium within 2-4 weeks after starting ACE inhibitor or ARB 1
The European Renal Association suggests monitoring daily weights during acute phase, weekly to biweekly during stabilization, and considering cystatin C measurement in patients with low muscle mass or sarcopenia 2